Overview

Terray Therapeutics focuses on discovering and developing small molecule drugs using a combination of experimental techniques and computational methods. The company generates a large dataset of over two billion unique target-ligand binding measurements, with 150 million new measurements added each month. This extensive data allows for precise predictions of molecular properties through deep learning models. Terray employs a fast design-make-test-analyze cycle, completing each cycle in under a month, which enables the efficient exploration of chemical compounds to identify effective small molecules for various therapeutic targets. While the primary focus is on immunology, Terray collaborates with pharmaceutical and biotech companies to tackle a wide range of therapeutic challenges, creating additional revenue opportunities alongside its internal drug discovery projects.

💡 Want to apply to Terray Therapeutics?

You have ways to get a Terray Therapeutics referral from your network.

Get referrals →

Simplify's Take

What believers are saying

• Terray raised $120 million in Series B funding, boosting financial stability.
• Partnerships with Gilead and Bristol Myers Squibb expand Terray's reach and resources.
• Investment from NVIDIA enhances Terray's generative AI capabilities for drug discovery.

What critics are saying

• Increased competition from AI-driven biotech firms like Insilico Medicine.
• Potential over-reliance on partnerships with large pharmaceutical companies.
• High costs of maintaining computational infrastructure could strain financial resources.

What makes Terray Therapeutics unique

• Terray integrates experimentation and computation for efficient small molecule drug discovery.
• The company generates over 150 million new target-ligand binding measurements monthly.
• Terray's rapid design-make-test-analyze cycle takes less than a month per target.

Help us improve and share your feedback! Did you find this helpful?

YesNo

Funding

Total Funding

$195M

Above

Industry Average

Funded Over

3 Rounds

$120,000,000

Series B

Oct 2024

Series B funding is typically for startups that have proven their business model and need more funding to expand rapidly—often by entering new markets or adding more products. Investors are usually venture capital firms that specialize in later-stage investments.

Series B Funding Comparison

Above Average

Industry standards

Ind Avg. $35M

$4M

$30M

$45M

$65M

$100M

$120M

View all funding stages